Final number of Consideration Shares and Update on total voting rights

Malibu Life Holdings completed a true-up related to its September 12, 2025 acquisition of Malibu Life Reinsurance SPC, confirming the final number of Consideration Shares at 1,889,809. An additional 21,004 Ordinary Shares (Balancing Action Shares) will be allotted to The Daniel S. Loeb Revocable Trust, bringing the Company's issued Ordinary Shares to 17,071,062 and B Shares to 11,380,708; total voting rights will be 28,451,770 following expected Admission to trading on the London Stock Exchange by 08:00 on 2 February 2026. The Company holds no treasury shares.

Analysis

Market structure: This is housekeeping — a 21,004 share balancing issue equals ~0.12% of ordinary shares (21,004/17,071,062) and produces no meaningful dilution or liquidity shock. The only direct beneficiary is The Daniel S. Loeb Revocable Trust (insider alignment); investors should view this as a completed acquisition true‑up rather than macro market news. Total voting rights now 28,451,770 — use as denominator for DTR thresholds.

Risk assessment: Tail risks are concentrated: a Loeb-led activist campaign, undisclosed contingent liabilities in the acquired reinsurance SPC, or further true‑ups that change cash flows could move price >30% (low probability, high impact). Immediate (days) impact should be nil; watch short term (weeks/months) for DTR beneficial‑ownership filings and any 60‑day post‑deal disclosures; long term (quarters) is where integration, capital adequacy and underwriting results will matter. Hidden dependency: the true‑up mechanism signals valuation uncertainty — further adjustments or escrow releases are possible.

Trade implications: Do not trade solely on this announcement; instead set concrete event triggers: (a) beneficial ownership filings at 3%/5% and (b) any board/strategic‑review announcement within 60 days. If triggers hit, take small, event‑driven positions (1–3% portfolio) with 6–12 month time horizons and 8–12% stop‑losses; for sector exposure prefer large, liquid reinsurers (e.g., RNR, RE) for 6–12 months given reinsurance pricing dynamics.

Contrarian angles: The market will treat this as administrative, missing the signal that Loeb’s trust now holds consideration — even a small stake increases probability of future activism which historically produces 15–40% rerates within 6–12 months. If the company trades <0.7x P/TBV or materially below NAV post‑disclosure, that would be an asymmetric long; conversely, undisclosed SPC liabilities could create downside, so size positions small until governance clarity arrives.

Key Decisions for Investors

• Do not trade Malibu Life on this notice alone. Add to watchlist and automatically monitor FCA DTR beneficial‑ownership filings for the Trust over the next 30 calendar days; if ownership is disclosed >=3%, establish a 1–1.5% long position in the stock, target 20–35% upside over 6–12 months, implement a hard stop‑loss at 10%.
• If the company announces a strategic review, board changes, or a shareholder return program within 60 days, increase exposure to 2–3% as an event‑driven play but use a 3–6 month call‑spread (buy ATM call, sell 25–35% OTM) to cap downside and fund part of the premium — max portfolio risk 2%.
• Rotate 1–3% of insurance/reinsurance exposure into large-cap, liquid reinsurers: buy RNR (RenaissanceRe) 1–2% and RE (Everest Re) 1% for a 6–12 month horizon to capture sector rerating; hedge 0.5% of position by shorting a broad insurance ETF if available to limit beta risk.
• Avoid options or leveraged positions on Malibu Life until liquidity/events confirm material activism or strategic actions; if seeking asymmetric upside, buy 12‑month calls only after an event trigger and cap allocation to <=0.5% of portfolio.